PhySoft AMS manages anemia for dialysis patients, improving patient outcomes, while reducing ESA costs and hospitalizations. It recommends a optimum ESA dosage to reach and maintain the Hgb level chosen by the clinician.
PhySoft AMS manages anemia for dialysis patients, improving patient outcomes, while reducing ESA costs and hospitalizations. It recommends a optimum ESA dosage to reach and maintain the Hgb level chosen by the clinician.
Dr. David Johnson is currently Director of Renal Medicine at Princess Alexandra Hospital in Brisbane, Australia. He specializes in peritoneal dialysis outcomes, cardiovascular risk factor modification in uraemia, renal transplantation, dialysis unit infec
Over a decade of work and at a cost of over $30 million the Wearable Artificial Kidney was developed for the treatment of kidney disease. The device, which has been clinically tested in Europe, improves outcomes and has the potential to dramatically reduc